Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00853658 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 7,064
- Enrollment target
NCT00853658: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT00853658 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 7,064 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (815% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00853658, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,064 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV.
Primary Outcome
Number of participants that had first occurrence of the composite endpoint, which is defined as either CV death or HF hospitalization due to HF.
Interventions
- DRUG Aliskiren
- DRUG Enalapril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,064 participants |
| Start Date | 2009-03 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
What the finished NCT00853658 record still lists
NCT00853658 is an interventional study that assigns participants to a tested intervention. Its 7,064 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (815% higher).
The record links to 0 conditions, and to 2 interventions - of which Aliskiren is the first listed.
NCT00853658 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00853658 about?
NCT00853658 is a clinical study titled "Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure". The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV.
What is the current status of trial NCT00853658?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,064 participants. The study started on 2009-03. Estimated completion is 2015-10.
What interventions are being tested in trial NCT00853658?
The interventions under investigation include: Aliskiren (DRUG), Enalapril (DRUG).
Who is sponsoring clinical trial NCT00853658?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00853658's enrollment target sits among peer trials
7,064 34th of 2000 higher than 1,967 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06843720 · 7,100 participants · NA
Expanding Access to Cervical Cancer Screening Through Primary HR-HPV Testing and Self-sampling: a Multicomponent Intervention for Safety Net Health Systems
- NCT00260585 · 7,000 participants
Esophageal Cancer Risk Registry
- NCT04118660 · 7,000 participants
Thoracic Specimen Registry
- NCT07106879 · 7,000 participants
Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia